Our data support a model whereby ATF3 induction in the mononuclear cells (presumably reflecting a reactive stroma) alters their gene expression and bioactivities, contributing to host-enhanced metastasis.
This expression of ATF3 predicted poor clinical outcome in a cohort of patients, suggesting that dampening ATF3 expression in the host may be a potential therapeutic approach.